ES2138603T3 - Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano. - Google Patents

Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano.

Info

Publication number
ES2138603T3
ES2138603T3 ES93104633T ES93104633T ES2138603T3 ES 2138603 T3 ES2138603 T3 ES 2138603T3 ES 93104633 T ES93104633 T ES 93104633T ES 93104633 T ES93104633 T ES 93104633T ES 2138603 T3 ES2138603 T3 ES 2138603T3
Authority
ES
Spain
Prior art keywords
human plasma
factors
complex
combin
proto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93104633T
Other languages
English (en)
Inventor
Silvana Arrighi
Francesco Norelli
Maria Giuseppina Borri
Enzo Bucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ISI IST SIEROVACCINOGENO ITAL
Sclavo SpA
Original Assignee
ISI IST SIEROVACCINOGENO ITAL
Sclavo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ISI IST SIEROVACCINOGENO ITAL, Sclavo SpA filed Critical ISI IST SIEROVACCINOGENO ITAL
Application granted granted Critical
Publication of ES2138603T3 publication Critical patent/ES2138603T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE OFRECE LA DESCRIPCION DE UN PROCESO PARA LA PURIFICACION DEL FACTOR IX, DEL FACTOR X Y DEL FACTOR II A PARTIR DEL PLASMA HUMANO O DE FRACCIONES DEL MISMO, EN EL UNA SOLUCION QUE CONTENGA FACTORES DE COMPLEJO DE PROTROMBINA SE PURIFICA MEDIANTE REPETIDAS SEPARACIONES CROMATOGRAFICAS DE INTERCAMBIO DE IONES SEGUIDAS POR CROMATOGRAFIA DE ABSORCION SOBRE LOS IONES DE METAL.
ES93104633T 1992-03-27 1993-03-22 Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano. Expired - Lifetime ES2138603T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITFI920078A IT1262899B (it) 1992-03-27 1992-03-27 Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano

Publications (1)

Publication Number Publication Date
ES2138603T3 true ES2138603T3 (es) 2000-01-16

Family

ID=11350034

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93104633T Expired - Lifetime ES2138603T3 (es) 1992-03-27 1993-03-22 Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano.

Country Status (6)

Country Link
US (1) US5378365A (es)
EP (1) EP0617049B1 (es)
AT (1) ATE184018T1 (es)
DE (1) DE69326227T2 (es)
ES (1) ES2138603T3 (es)
IT (1) IT1262899B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3336631A1 (de) * 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
DE19504852C2 (de) * 1995-02-15 2003-01-23 Octapharma Ag Lachen Verfahren zur Reinigung Vitamin K-abhängiger Gerinnungsfaktoren durch Affinitäts-Chromatographie
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
DE59712322D1 (de) * 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
DE19625642A1 (de) * 1996-06-26 1998-01-08 Max Planck Gesellschaft Verfahren zur Herstellung einer Antidotausgangssubstanz für natürliche und synthetische Thrombininhibitoren
AT409334B (de) * 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
ITBO20010426A1 (it) * 2001-07-06 2003-01-06 Alfa Wassermann Spa Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico
SE0203551D0 (sv) * 2002-12-02 2002-12-02 Biovitrum Ab Prothrombin purification
GB0614315D0 (en) 2006-07-19 2006-08-30 Ge Healthcare Bio Sciences Ab Chromatography columns, systems and methods
US9597610B2 (en) * 2007-03-09 2017-03-21 Ge Healthcare Bioprocess R&D Ab Packing system and method for chromatography columns
GB0704603D0 (en) * 2007-03-09 2007-04-18 Ge Healthcare Bio Sciences Ab Packing system and method for chromatography columns
US9597611B2 (en) * 2007-03-09 2017-03-21 Ge Healthcare Bioprocess R&D Ab Packing system and method for chromatography columns
GB0710321D0 (en) 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
US7934704B2 (en) * 2007-10-16 2011-05-03 Environmental Dynamics, Inc. Retrievable diffuser module with internal ballast/buoyancy chamber
RU2544860C2 (ru) 2008-12-02 2015-03-20 Ново Нордиск Хелс Кеа Аг Очистка полипептидов
KR20120118028A (ko) 2010-01-18 2012-10-25 노보 노르디스크 헬스 케어 악티엔게젤샤프트 혈액 응고 인자의 정제
WO2012082933A1 (en) 2010-12-15 2012-06-21 Baxter International, Inc. Eluate collection using conductivity gradient
CN107915769A (zh) 2011-03-29 2018-04-17 葛兰素史密斯克莱有限责任公司 用于蛋白纯化的缓冲液体系
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DE3914869C1 (es) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5286849A (en) * 1992-07-14 1994-02-15 Alpha Therapeutic Corporation Purification of factor IX

Also Published As

Publication number Publication date
DE69326227D1 (de) 1999-10-07
DE69326227T2 (de) 2000-02-17
ITFI920078A0 (it) 1992-03-27
US5378365A (en) 1995-01-03
IT1262899B (it) 1996-07-22
EP0617049A1 (en) 1994-09-28
EP0617049B1 (en) 1999-09-01
ATE184018T1 (de) 1999-09-15
ITFI920078A1 (it) 1993-09-27

Similar Documents

Publication Publication Date Title
ES2138603T3 (es) Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano.
DE69031748D1 (de) Plasmabehandlung mit Metallmasken-Integration
ES2032807T3 (es) Pelicula de baja emisividad para tratamiento a alta temperatura.
NO20056021L (no) Anvendelse av CS-866 til fremstilling av et medikament
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
AR245684A1 (es) Procedimiento mejorado de hidrogenolisis/deshidrohalogenacion
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
PA8464901A1 (es) Procesos para la sintesis de 1,3-dioles
ES2085468T3 (es) Albuterol r(-) opticamente puro para tratar el asma.
AU7619291A (en) Use of baclofen for obtaining medicaments for the treatment of angina pectoris
ES2051675T1 (es) Uso de ciertos herbicidas en el tratamiento del cancer y produccion de protoporfirina ix.
MX9302836A (es) Proteasas alcalinas, bacterias que las producen, proceso para laproduccion de estas proteasas, usos de estas proteasas alcalinas ycomposiciones detergentes que las contienen.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
ES2187534T3 (es) Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida.
ES2073501T3 (es) Procedimiento para el tratamiento de laminas de poliolefina.
MX9305992A (es) Modificacion con laser de superficies de objectos a traves de ablacion.
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
ES2129835T3 (es) Purificacion de propofol.
CA2082034A1 (en) Absorption of materials
ATE167804T1 (de) Verwendung von nickel und bromide ionen für die behandlung von psoriasis
ES2134430T3 (es) Procedimiento de fluoracion.
ES2053942T3 (es) Empleo de aductos de oxido de 1,2-butileno en compuestos organicos h-azidas como lubricantes y lubricantes que contienen estos aductos.
ES2121204T3 (es) Preparacion de fluoro-nucleosidos e intermedios para su uso en ella.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 617049

Country of ref document: ES